Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients
2003-01-01 Danese, S; Katz, Ja; Saibeni, S; Papa, A; Gasbarrini, A; Vecchi, M; Fiocchi, C
IBD Golimumab in ulcerative colitis: a 'menage a trois' of drugs
2013-01-01 Danese, S
Functional hyporesponsiveness of Lamina Propria T cells (LPT) is reflected by a muted tyrosine phosphorylation of the T Cell Receptor (TCR) signaling cascade
2003-01-01 Reyes, Bmr; Danese, S; Levine, Ad
The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation
2008-01-01 Lust, M; Vulcano, M; Danese, S
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease
2013-01-01 Cammarota, T; Ribaldone, Dg; Resegotti, A; Repici, A; Danese, S; Fiorino, G; Sarno, A; Robotti, D; Debani, P; Bonenti, G; Pellicano, R; Andrealli, A; Sapone, N; Simondi, D; Bresso, F; Astegiano, M
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience
2011-01-01 Danese, S; Colombel, Jf; Reinisch, W; Rutgeerts, Pj; Fiorino, Gionata
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
2018-01-01 Bonovas, S; Lytras, T; Nikolopoulos, G; Peyrin-Biroulet, L; Danese, S
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
2018-01-01 Pouillon, L; Van Stappen, J; Bossuyt, P; Danese, S; Peyrin-Biroulet, L
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences
2019-01-01 Salem, F; Kindt, N; Marchesi, Jr; Netter, P; Lopez, A; Kokten, T; Danese, S; Jouzeau, Jy; Peyrin-Biroulee, L; Moulin, D
Biosimilars of adalimumab: the upcoming challenge in IBD
2019-01-01 Fiorino, G; Gilardi, D; Correale, C; Furfaro, F; Roda, G; Loy, L; Argollo, M; Allocca, M; Peyrin-Biroulet, L; Danese, S
Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
2021-01-01 Kotze, Paulo Gustavo; Peyrin-Biroulet, Laurent; Danese, Silvio
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience
2017-01-01 Allocca, Mariangela; Bonifacio, Cristiana; Fiorino, Gionata; Spinelli, Antonino; Furfaro, Federica; Balzarini, Luca; Bonovas, Stefanos; Danese, Silvio
Intestinal microbiota in inflammatory bowel disease: Friend of foe?
2011-01-01 Fava, F; Danese, S
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
2014-01-01 M. Vecchi, V. Annese; behalf of the Italian Group for the Study of IBD, On; Bossa, IG IBD Governing B. o. a. r. d. Collaborators: F.; Calabrese, E.; Daperno, M.; Rizzello, F.; Rispo, A.; Saibeni, S.; Armuzzi, A.; Biancone, L.; Castiglione, F.; Comberlato, M.; Cucchiara, S.; Danese, S.; D'Incà, R.; Gionata, Fiorino; Walter, Fries; Gionchetti, P.; Kohn, A.; Latella, G.; Meucci, G.; Orlando, A.; Papi, C.; Principi, B.
Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation
2011-01-01 Vetrano, S; Ploplis, Va; Sala, E; Sandoval-Cooper, M; Donahue, Dl; Correale, C; Arena, V; Spinelli, A; Repici, A; Malesci, A; Castellino, Fj; Danese, S
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective
2020-01-01 Allen, Pb; Bonovas, S; Danese, S; Peyrin-Biroulet, L
Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study
2021-01-01 Piovani, Daniele; Pansieri, Claudia; Peyrin-Biroulet, Laurent; Danese, Silvio; Bonovas, Stefanos
Successful treatment of fistulizing Crohn's disease with certolizumab pegol
2008-01-01 Danese, S.; Stefanelli, T.; Omodei, P.; Zatelli, S.; Bonifacio, C.; Balzarini, L.; Repici, A.; Malesci, A.
Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey
2019-01-01 Peyrin-Biroulet, L; Lonnfors, S; Avedano, L; Danese, S
Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells
2013-01-01 Jovani, M; Danese, S
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients | 1-gen-2003 | Danese, S; Katz, Ja; Saibeni, S; Papa, A; Gasbarrini, A; Vecchi, M; Fiocchi, C | |
| IBD Golimumab in ulcerative colitis: a 'menage a trois' of drugs | 1-gen-2013 | Danese, S | |
| Functional hyporesponsiveness of Lamina Propria T cells (LPT) is reflected by a muted tyrosine phosphorylation of the T Cell Receptor (TCR) signaling cascade | 1-gen-2003 | Reyes, Bmr; Danese, S; Levine, Ad | |
| The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation | 1-gen-2008 | Lust, M; Vulcano, M; Danese, S | |
| Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease | 1-gen-2013 | Cammarota, T; Ribaldone, Dg; Resegotti, A; Repici, A; Danese, S; Fiorino, G; Sarno, A; Robotti, D; Debani, P; Bonenti, G; Pellicano, R; Andrealli, A; Sapone, N; Simondi, D; Bresso, F; Astegiano, M | |
| Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience | 1-gen-2011 | Danese, S; Colombel, Jf; Reinisch, W; Rutgeerts, Pj; Fiorino, Gionata | |
| Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis | 1-gen-2018 | Bonovas, S; Lytras, T; Nikolopoulos, G; Peyrin-Biroulet, L; Danese, S | |
| Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? | 1-gen-2018 | Pouillon, L; Van Stappen, J; Bossuyt, P; Danese, S; Peyrin-Biroulet, L | |
| Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences | 1-gen-2019 | Salem, F; Kindt, N; Marchesi, Jr; Netter, P; Lopez, A; Kokten, T; Danese, S; Jouzeau, Jy; Peyrin-Biroulee, L; Moulin, D | |
| Biosimilars of adalimumab: the upcoming challenge in IBD | 1-gen-2019 | Fiorino, G; Gilardi, D; Correale, C; Furfaro, F; Roda, G; Loy, L; Argollo, M; Allocca, M; Peyrin-Biroulet, L; Danese, S | |
| Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic | 1-gen-2021 | Kotze, Paulo Gustavo; Peyrin-Biroulet, Laurent; Danese, Silvio | |
| Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience | 1-gen-2017 | Allocca, Mariangela; Bonifacio, Cristiana; Fiorino, Gionata; Spinelli, Antonino; Furfaro, Federica; Balzarini, Luca; Bonovas, Stefanos; Danese, Silvio | |
| Intestinal microbiota in inflammatory bowel disease: Friend of foe? | 1-gen-2011 | Fava, F; Danese, S | |
| Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease | 1-gen-2014 | M. Vecchi, V. Annese; behalf of the Italian Group for the Study of IBD, On; Bossa, IG IBD Governing B. o. a. r. d. Collaborators: F.; Calabrese, E.; Daperno, M.; Rizzello, F.; Rispo, A.; Saibeni, S.; Armuzzi, A.; Biancone, L.; Castiglione, F.; Comberlato, M.; Cucchiara, S.; Danese, S.; D'Incà, R.; Gionata, Fiorino; Walter, Fries; Gionchetti, P.; Kohn, A.; Latella, G.; Meucci, G.; Orlando, A.; Papi, C.; Principi, B. | |
| Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation | 1-gen-2011 | Vetrano, S; Ploplis, Va; Sala, E; Sandoval-Cooper, M; Donahue, Dl; Correale, C; Arena, V; Spinelli, A; Repici, A; Malesci, A; Castellino, Fj; Danese, S | |
| Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective | 1-gen-2020 | Allen, Pb; Bonovas, S; Danese, S; Peyrin-Biroulet, L | |
| Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study | 1-gen-2021 | Piovani, Daniele; Pansieri, Claudia; Peyrin-Biroulet, Laurent; Danese, Silvio; Bonovas, Stefanos | |
| Successful treatment of fistulizing Crohn's disease with certolizumab pegol | 1-gen-2008 | Danese, S.; Stefanelli, T.; Omodei, P.; Zatelli, S.; Bonifacio, C.; Balzarini, L.; Repici, A.; Malesci, A. | |
| Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey | 1-gen-2019 | Peyrin-Biroulet, L; Lonnfors, S; Avedano, L; Danese, S | |
| Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells | 1-gen-2013 | Jovani, M; Danese, S |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista39385
Data di pubblicazione
- In corso di stampa9
- 2020 - 202711472
- 2010 - 201915948
- 2000 - 20097460
- 1990 - 19993485
- 1980 - 1989933
- 1970 - 197977
- 1959 - 19591
Editore
- Elsevier Inc.802
- Elsevier B.V.767
- John Wiley and Sons Inc524
- Springer Science and Business Med...516
- Oxford University Press483
- Lippincott Williams and Wilkins420
- Springer360
- MDPI347
- Elsevier Ltd330
- Springer Nature281
Rivista
- EUROPEAN UROLOGY529
- BLOOD372
- PLOS ONE312
- JOURNAL OF NEUROLOGY283
- EUROPEAN JOURNAL OF HEART FAILURE280
- NEUROLOGY268
- DIGESTIVE AND LIVER DISEASE245
- EUROPEAN HEART JOURNAL224
- MULTIPLE SCLEROSIS216
- SCIENTIFIC REPORTS212
Keyword
- Humans3553
- Male2080
- Female1864
- Middle Aged1472
- Aged1290
- Adult1100
- COVID-19629
- Retrospective Studies628
- Treatment Outcome603
- Prognosis481
Lingua
- eng28792
- ita1958
- fre64
- und55
- spa34
- ger25
- por12
- enm6
- rus6
- grc3
Accesso al fulltext
- no fulltext33605
- open3381
- reserved2292
- partially open99
- embargoed7
- mixed1